Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers

• Status: Terminated
• Trial end date: 1969-12-31

Summary

Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on the bioavailability of dabigatran etexilate,

Part 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe substrate for P-gp

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Dabigatran; Fexofenadine; Quinidine; Quinidine gluconate; Terfenadine